Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes.
[1]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015 Sep 22;6(28):25429-40.